This would be most likely to occur in older patients, says Murroughbut if you notice more bruises than normal or cuts that wont stop bleeding, definitely bring that to your doctors attention.
Jardiance has shown reduction in cardiovascular mortality and heart failure hospitalisations in clinical trials
Comprehensive Initial Evaluation: The tailoring process begins with an in-depth consultation
Lilly's oral GLP-1 orforglipron consistent with injectable GLP-1 medicines owenhaskins Apr 17, 2025 3 min read The topline Phase 3 results from Eli Lilly ACHIEVE-1 study, evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone, have revealed that orforglipron met the primary endpoint of superior A1C reduction compared to placebo at 40 weeks
To date, incretin-based approaches for obesity management appear as the most promising and rapidly developing (Supplementary Table 1), with innovations such as once-weekly (OW) injectable triple GIPR/GCGR/GLP-1R agonist retatrutide (LY3437943), cagrilintide (long-acting amylin analogue)/semaglutide 2.4 mg (CagriSema) combination, GCGR/GLP-1R dual agonists, high-dose oral semaglutide, and oral non-peptide GLP-1 receptor agonist orforglipron, with relevant implications in terms of patients compliance and environmental sustainability
UK Regulatory Position on GLP-1 Medicines and Cancer The Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency (EMA) maintain active surveillance of GLP-1 receptor agonists and have issued clear guidance regarding their safety profile, including cancer-related considerations
